Kiora Pharmaceuticals
KPRX
22 hedge funds and large institutions have $2.91M invested in Kiora Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 6 closing their positions.
344% more capital invested
Capital invested by funds: $655K → $2.91M (+$2.25M)
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
22% more funds holding
Funds holding: 18 → 22 (+4)
16.36% more ownership
Funds ownership: 8.59% → 24.95% (+16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$1.1M |
| 2 |
Two Sigma Investments
New York
|
+$223K |
| 3 |
Millennium Management
New York
|
+$186K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$167K |
| 5 |
HF
HRT Financial
New York
|
+$147K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$53.1K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$28.4K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$23.2K |
| 4 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
-$19.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$397 |
KPRX Hedge Fund Activity: Q2 2026 in Review
22 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2026, worth a combined $2.91M — up 344% from $655K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KPRX positions and 6 closed out — a net gain of 4 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $1.1M. The largest seller was Geode Capital Management, cutting an estimated $53.1K.
- 22 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2026, up from 18 in Q1 2026.
- Funds reported $2.91M of Kiora Pharmaceuticals stock for Q2 2026, up 344% quarter-over-quarter.
- 10 funds opened new Kiora Pharmaceuticals positions in Q2 2026 and 6 closed out, a net change of +4 holders.
- The largest Kiora Pharmaceuticals buyer in Q2 2026 was Perceptive Advisors, an estimated $1.1M added.
- The largest Kiora Pharmaceuticals seller in Q2 2026 was Geode Capital Management, an estimated $53.1K sold.
Based on aggregated 13F filings for Q2 2026.